Interaction between Chlamydia pneumoniae seropositivity, inflammation and risk factors for atherosclerosis in patients with severe coronary stenosis

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 66, Issue 6, 2006, Pages 523-534

  Yavuz, M T ^a   Yavuz, O ^a   Yazici, M ^a   Guler, S ^a   Ozhan, H ^a   Albayrak, S ^a   Coskun, A ^a  

^a ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

Author keywords

Adhesion molecules; Cytokines; Dyslipidemia; IL 6 levels

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FERRITIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; ORAL ANTIDIABETIC AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EVALUATION; FEMALE; GENSINI SCORE; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SERODIAGNOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTIBODIES, BACTERIAL; ATHEROSCLEROSIS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CORONARY STENOSIS; CYTOKINES; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; RISK FACTORS;

CHLAMYDOPHILA PNEUMONIAE;

EID: 33749022762     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510600931114     Document Type: Article

References (38)

1. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999;138:19-20.
2. Grayston JT, Campbell LA, Kuo CC, Mordhorst CH, Saikku P, Thom DH, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990;161:618-25.
3. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary disease. JAMA 1992;268:68-72.
4. Linnanmaki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae - specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993;87:1130-4.
5. Hoffmeister A, Rothenbacher D, Wanner P, Bode G, Persson K, Brenner H, et al. Seropositivity to chlamydial lipopolysaccharide and Chlamydia pneumoniae, systemic inflammation and stable coronary artery disease. J Am Coll Cardiol 2000;35:112-18.
6. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999;9:1161-4.
7. Haider AW, Wilson PWF, Larson MG, Evans JC, Michelson EL, Wolf PA, et al. The Association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study. J Am Coll Cardiol 2002;40:1408-13.
8. Young JL, Libby P, Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002;88:554-67.
9. Kohara K, Tabara Y, Yamamoto Y, Igase M, Miki T. Chlamydia pneumoniae seropositivity is associated with increased plasma levels of soluble cellular adhesion molecules in community-dwelling subjects: the Shimanami Health Promoting Program (J-SHIPP) study. Stroke 2002;33:1474-9.
10. Kaukoranta-Tolvanen SSE, Teppo AM, Laitinen K, Saikku P, Linnavuori K, Leinonen M. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog 1996;21:215-21.
11. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease - meta-analyses of prospective studies. JAMA 1998;279:1477-82.
12. Leinonen M, Saikku P. Interaction of Chlamydia pneumoniae infection with other risk factors of atherosclerosis. Am Heart J 1999;138:504-6.
13. Laurila A, Bloigu A, Nayha S, Hassi J, Leinonen M, Saikku P. Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:2910-13.
14. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
15. Oberman A, Jones WB, Riley CP, Reeves TJ, Sheffield LT, Turner ME. Natural history of coronary artery disease. Bull NY Acad Med 1972;48:1109-25.
16. Gensini GG, Kelly AE. Reassessment of contrast agent for coronary angiography. Curr Ther Res Clin Exp 1976;19:631-6.
17. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001;103:1064-70.
18. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 2003;21:1787-803.
19. Thom DH, Wang SP, Grayston JT, Siscovick DS, Stewart DK, Kronmal RA, et al. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb 1991;11:547-51.
20. Jaremo A, Richter A. Chlamydia pneumoniae IgG and the severity of coronary atherosclerosis. Eur J Intern Med 2004;15:508-10.
21. Romano S, Penco M, Fratini S, Di Pietro M, Sessa R, Del Piano M, et al. Chlamydia pneumoniae infection is associated with coronary artery disease but not implicated in inducing plaque instability. Int J Cardiol 2004;95:95-9.
22. Nishimura M, Hashimoto T, Kobayashi H, Fukuda T, Okino K, Yamamoto N, et al. Close association of Chlamydia pneumoniae IgA seropositivity by ELISA with the presence of coronary artery stenosis in haemodialysis patients. Nephrol Dial Transplant 2005;20:1944-50.
23. Halme S, von Hertzen L, Bloigu A, Kaprio J, Koskenvuo M, Leinonen M, et al. Chlamydia pneumoniae-specific cell-mediated and humoral immunity in healthy people. Scand J Immunol 1998;47:517-20.
24. Schumacher A, Seljeflot I, Lerkerod AB, Sommervoll L, Otterstad JE, Arnesen H. Chlamydia LPS and MOMP seropositivity are associated with different cytokine profiles in patients with coronary heart disease. Eur J Clin Invest 2005;35:431-7.
25. Paltiel O, Kark JD, Leinonen M, Saikku P. High prevalence of antibodies to Chlamydia pneumoniae: determinants of IgG and IgA seropositivity among Jerusalem residents. Epidemiol Infect 1995;114:465-73.
26. Ferrari M, Poli A, Olivieri M, Tardivo S, Biasin C, Balestreri F, et al. Seroprevalence of Chlamydia pneumoniae antibodies in a young adult population sample living in Verona. European Community Respiratory Health Survey (ECRHS) Verona. Infection 2000;28:38-41.
27. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15.
28. Laurila A, Bloigu A, Nayha S, Hassi J, Leinonen M, Saikku P. Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:2910-13.
29. Turkoglu C, Sonmez E, Aydinli A. Relationship between dyslipidemia, C-reactive protein and serological evidence of Chlamydia pneumoniae in Turkish patients with coronary artery diseases. New Microbiol 2004;27:229-34.
30. Beisal WR. Metabolic response to infection. Ann Rev Med 1975;26:9-20.
31. Koh WP, Taylor MB, Hughes K, Chew SK, Fong CW, Phoon MC, et al. Seroprevalence of IgG against Chlamydia pneumoniae in Chinese Malays and Asian Indians in Singapore. Int J Epidemiol 2002;31:1001-7.
32. Netea MG, Selzman CH, Kullberg BJ, Galama JM, Weinberg A, Stalenhoef AF, et al. Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. Eur J Immunol 2000;30:541-9.
33. Haddy N, Sass C, Droesch S, Zaiou M, Siest G, Ponthieux A, et al. IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis 2003;170:277-83.
34. Schumacher A, Seljeflot I, Lerkerod AB, Sommervoll L, Otterstad JE, Arnesen H. Positive Chlamydia pneumoniae serology is associated with elevated levels of tumor necrosis factor alpha in patients with coronary heart disease. Atherosclerosis 2002;164:153-60.
35. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br Med J 1996;312:1061-5.
36. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997;6:315-25.
37. Schumacher A, Seljeflot I, Lerkerod AB, Sommervoll L, Otterstad JE, Arnesen H. Does infection with Chlamydia pneumoniae and/or Helicobacter pylori increase the expression of endothelial cell adhesion molecules in humans? Clin Microbiol Infect 2002;8:654-61.
38. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999;103:747-53.